{"url_path":"/sec/lgnd/8-k/2026-05-18/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-18","source_url":"https://www.sec.gov/Archives/edgar/data/886163/0001193125-26-228003-index.html","accession_number":"0001193125-26-228003","cik":"0000886163","ticker":"LGND","issuer_name":"LIGAND PHARMACEUTICALS INC","edgar_url":"https://www.sec.gov/Archives/edgar/data/886163/0001193125-26-228003-index.html","primary_entity_key":"0000886163","primary_entity_name":"LIGAND PHARMACEUTICALS INC"},"word_count":110,"has_tables":true,"body_markdown":"Item 9.01.\n\nFinancial Statements and Exhibits.\n\n(d) Exhibits.\n\n \n\nExhibit\n  \nDescription\n\n2.1\n  \n[Amendment No. 1 to the Agreement and Plan of Merger, dated as of May 16, 2026, by and among XOMA Royalty Corporation, XOMA Royalty Holdings Corporation, Ligand Pharmaceuticals Incorporated and Flex Merger Sub, Inc.](d86489dex21.htm)\n\n104\n  \nCover Page Interactive Data File (embedded within the Inline XBRL document).\n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\n \n\n \nLIGAND PHARMACEUTICALS INCORPORATED\n\nDate: May 17, 2026\n \n\n \nBy:\n \n\n/s/ Andrew Reardon\n\n \n\n \nName:\n \nAndrew Reardon\n\n \n\n \nTitle:\n \nChief Legal Officer and Secretary"}